1
|
Cousino M, Blume E, Smith C, Lim H, Yu S, Lowery R, Viers S, Uzark K, Fredericks E, Miller V, Schumacher K. Palliative and End of Life Care Preferences in Adolescents and Young Adults with Heart Failure. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
2
|
Menon S, Ellis C, Poudel S, Johnson J, Szabo A, George B, Kevin Kelly W, Grant S, McPherson J, Cristofanilli M, Hoimes C, Gutierrez M, Doudement J, Chan L, Singal G, Alexander B, Miller V, Sohal D. B08 Impact of Concurrent STK11 Loss and c-MYC Amplification in Metastatic Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2020. [DOI: 10.1016/j.jtho.2019.12.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
3
|
Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Morano F, Fucà G, Nikolinakos P, Drilon A, Hechtman JF, Christiansen J, Gowen K, Frampton GM, Gasparini P, Rossini D, Gigliotti C, Kim ST, Prisciandaro M, Hodgson J, Zaniboni A, Chiu VK, Milione M, Patel R, Miller V, Bardelli A, Novara L, Wang L, Pupa SM, Sozzi G, Ross J, Di Bartolomeo M, Bertotti A, Ali S, Trusolino L, Falcone A, de Braud F, Cremolini C. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Ann Oncol 2019. [PMID: 29538669 DOI: 10.1093/annonc/mdy090] [Citation(s) in RCA: 70] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Background Recognition of rare molecular subgroups is a challenge for precision oncology and may lead to tissue-agnostic approval of targeted agents. Here we aimed to comprehensively characterize the clinical, pathological and molecular landscape of RET rearranged metastatic colorectal cancer (mCRC). Patients and methods In this case series, we compared clinical, pathological and molecular characteristics of 24 RET rearranged mCRC patients with those of a control group of 291 patients with RET negative tumors. RET rearranged and RET negative mCRCs were retrieved by systematic literature review and by taking advantage of three screening sources: (i) Ignyta's phase 1/1b study on RXDX-105 (NCT01877811), (ii) cohorts screened at two Italian and one South Korean Institutions and (iii) Foundation Medicine Inc. database. Next-generation sequencing data were analyzed for RET rearranged cases. Results RET fusions were more frequent in older patients (median age of 66 versus 60 years, P = 0.052), with ECOG PS 1-2 (90% versus 50%, P = 0.02), right-sided (55% versus 32%, P = 0.013), previously unresected primary tumors (58% versus 21%, P < 0.001), RAS and BRAF wild-type (100% versus 40%, P < 0.001) and MSI-high (48% versus 7%, P < 0.001). Notably, 11 (26%) out of 43 patients with right-sided, RAS and BRAF wild-type tumors harbored a RET rearrangement. At a median follow-up of 45.8 months, patients with RET fusion-positive tumors showed a significantly worse OS when compared with RET-negative ones (median OS 14.0 versus 38.0 months, HR: 4.59; 95% CI, 3.64-32.66; P < 0.001). In the multivariable model, RET rearrangements were still associated with shorter OS (HR: 2.97; 95% CI, 1.25-7.07; P = 0.014), while primary tumor location, RAS and BRAF mutations and MSI status were not. Conclusions Though very rare, RET rearrangements define a new subtype of mCRC that shows poor prognosis with conventional treatments and is therefore worth of a specific management.
Collapse
Affiliation(s)
- F Pietrantonio
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.
| | - F Di Nicolantonio
- Department of Oncology, University of Torino, Candiolo, Italy; ECMO, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy
| | - A B Schrock
- Clinical Development, Foundation Medicine, Inc., Cambridge, USA
| | - J Lee
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - F Morano
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - G Fucà
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - P Nikolinakos
- Medical Oncology, University Cancer & Blood Center, Athens
| | - A Drilon
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - J F Hechtman
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA
| | | | - K Gowen
- Clinical Development, Foundation Medicine, Inc., Cambridge, USA
| | - G M Frampton
- Clinical Development, Foundation Medicine, Inc., Cambridge, USA
| | - P Gasparini
- Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - D Rossini
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
| | - C Gigliotti
- Department of Oncology, University of Torino, Candiolo, Italy; ECMO, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy
| | - S T Kim
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - M Prisciandaro
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - J Hodgson
- Medical Oncology, University Cancer & Blood Center, Athens
| | - A Zaniboni
- Department of Medical Oncology, Fondazione Poliambulanza, Brescia, Italy
| | - V K Chiu
- Department of Internal Medicine, University of New Mexico, Albuquerque, USA
| | - M Milione
- Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - R Patel
- Department of Diagnostics, Ignyta, Inc., San Diego, USA
| | - V Miller
- Clinical Development, Foundation Medicine, Inc., Cambridge, USA
| | - A Bardelli
- Department of Oncology, University of Torino, Candiolo, Italy; ECMO, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy
| | - L Novara
- ECMO, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy
| | - L Wang
- Department of Pathology, St Jude Children's Research Hospital, Memphis, USA
| | - S M Pupa
- Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - G Sozzi
- Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - J Ross
- Clinical Development, Foundation Medicine, Inc., Cambridge, USA
| | - M Di Bartolomeo
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - A Bertotti
- Department of Oncology, University of Torino, Candiolo, Italy; ECMO, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy
| | - S Ali
- Clinical Development, Foundation Medicine, Inc., Cambridge, USA
| | - L Trusolino
- Department of Oncology, University of Torino, Candiolo, Italy; ECMO, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy
| | - A Falcone
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
| | - F de Braud
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
| | - C Cremolini
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
| |
Collapse
|
4
|
Madison R, Schrock A, Gregg J, Carson K, Castellanos E, Singal G, Miller V, Ali S, Alexander B, Chung J. P1.01-23 Retrospective Analysis of Real-World Clinico-Genomic Data for Clinical Impact of Genomic Profiling of ctDNA in NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
5
|
Ou S, Schrock A, Bocharov E, Lee J, Madison R, Gay L, Miller V, Alexander B, Husain H, Riess J, Ali S, Velcheti V. P1.01-86 Occurrence of de Novo Dual HER2/HER3 or HER2/EGFR TMD Mutations: Extending the Spectrum of Targetable Mono-HER2 TMD in NSCLC? J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
6
|
Negrao M, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Hu S, Elamin Y, Le X, Goldberg M, Wu C, Zhang J, Barreto D, Rinsurongkawong W, Simon G, Roth J, Swisher S, Lee J, Tsao A, Papadimitrakopoulou V, Gibbons D, Glisson B, Miller V, Alexander B, Frampton G, Albacker L, Shames D, Zhang J, Heymach J. MA03.05 BRAF Mutations Are Associated with Increased Benefit from PD1/PDL1 Blockade Compared with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
7
|
Hemmerich A, Madison R, Klempner S, Sokol E, Severson E, Miller V, Lee J, Ou S, Alexander B, Schrock A, Ross J, Ali S. Genomic profiling of diffuse gastric carcinoma (DGC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz154.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Salem M, Juckett L, Schrock A, Ross J, Puccini A, Grothey A, Lee J, Miller V, Madison R, Ali S. Landscape of FMS-like tyrosine kinase 3 (FLT3) and associated molecular alterations in 44,766 gastrointestinal (GI) cancers. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz154.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
9
|
Myer P, Lee J, Madison R, Newberg J, Ross J, Chung J, Albacker L, Alexander B, Miller V, Schrock A, Mitchell E, Frampton G, Ali S. Comprehensive genomic profiling (CGP) defines the genomic landscape of colorectal cancer (CRC) in individuals of African ancestry. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz154.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Schrock A, Pavlick D, Rosenzweig M, Erlich R, Albacker L, Frampton G, Ross J, Miller V, Ali S, Ou S. MA16.05 MET Kinase Domain Rearrangements (KDRE) in Non-Small Cell Lung Cancer (NSCLC) Identified Through Comprehensive Genomic Profiling (CGP). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.451] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
11
|
Chu L, Kelly K, Gandara D, Lara P, Borowsky A, Meyers F, Mcpherson J, Erlich R, Almog N, Schrock A, Ali S, Ross J, Miller V, Heilmann A, Riess J. P3.13-26 Outcomes of Patients with Metastatic Lung Cancer Presented in a Multidisciplinary Molecular Tumor Board. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1867] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
12
|
Friedman PC, Miller V, Fridman G, Fridman A. Use of cold atmospheric pressure plasma to treat warts: a potential therapeutic option. Clin Exp Dermatol 2018; 44:459-461. [PMID: 30264440 DOI: 10.1111/ced.13790] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/15/2018] [Indexed: 12/11/2022]
Affiliation(s)
- P C Friedman
- The Skin Center Dermatology Group, 200 E Eckerson Rd, New City, NY, 10956, USA
| | - V Miller
- C&J Nyheim Plasma Institute, Drexel University, Camden, NJ, USA
| | - G Fridman
- C&J Nyheim Plasma Institute, Drexel University, Camden, NJ, USA
| | - A Fridman
- C&J Nyheim Plasma Institute, Drexel University, Camden, NJ, USA
| |
Collapse
|
13
|
Ross JS, Gay LM, Wang K, Vergilio JA, Suh J, Ramkissoon S, Somerset H, Johnson JM, Russell J, Ali S, Schrock AB, Fabrizio D, Frampton G, Miller V, Stephens PJ, Elvin JA, Bowles DW. Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies. Ann Oncol 2018; 28:2539-2546. [PMID: 28961851 PMCID: PMC5834110 DOI: 10.1093/annonc/mdx399] [Citation(s) in RCA: 72] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Background Relapsed/metastatic salivary gland carcinomas (SGCs) have a wide diversity of histologic subtypes associated with variable clinical aggressiveness and response to local and systemic therapies. We queried whether comprehensive genomic profiling could define the tumor subtypes and uncover clinically relevant genomic alterations, revealing new routes to targeted therapies for patients with relapsed and metastatic disease. Patients and methods From a series of 85 686 clinical cases, DNA was extracted from 40 µm of formalin-fixed paraffin embedded (FFPE) sections for 623 consecutive SGC. CGP was carried out on hybridization-captured, adaptor ligation-based libraries (mean coverage depth, >500×) for up to 315 cancer-related genes. Tumor mutational burden was determined on 1.1 Mb of sequenced DNA. All classes of alterations, base substitutions, short insertions/deletions, copy number changes, and rearrangements/fusions were determined simultaneously. Results The clinically more indolent SGC including adenoid cystic carcinoma, acinic cell carcinoma, polymorphous low-grade adenocarcinoma, mammary analog secretory carcinoma, and epithelial-myoepithelial carcinomas have significantly fewer genomic alterations, TP53 mutations, and lower tumor mutational burden than the typically more aggressive SGCs including mucoepidermoid carcinoma, salivary duct carcinoma, adenocarcinoma, not otherwise specified, carcinoma NOS, and carcinoma ex pleomorphic adenoma. The more aggressive SGCs are commonly driven by ERBB2 PI3K pathway genomic alterations. Additional targetable GAs are frequently seen. Conclusions Genomic profiling of SGCs demonstrates important differences between traditionally indolent and aggressive cancers. These differences may provide therapeutic options in the future.
Collapse
Affiliation(s)
- J S Ross
- Department of Pathology, Foundation Medicine, Inc., Cambridge; Department of Pathology, Albany Medical Center, Albany, USA.
| | - L M Gay
- Department of Pathology, Foundation Medicine, Inc., Cambridge
| | - K Wang
- Center for Precision Medicine, Zhejiang University International Hospital, Hangzhou, China
| | - J A Vergilio
- Department of Pathology, Foundation Medicine, Inc., Cambridge
| | - J Suh
- Department of Pathology, Foundation Medicine, Inc., Cambridge
| | - S Ramkissoon
- Department of Pathology, Foundation Medicine, Inc., Cambridge
| | - H Somerset
- Department of Pathology, University of Colorado School of Medicine, Aurora
| | - J M Johnson
- Department of Medical Oncology, Thomas Jefferson University, Philadelphia
| | - J Russell
- Medical Oncology, Moffitt Cancer Center, Tampa
| | | | | | - D Fabrizio
- Clinical Genomics, Foundation Medicine, Inc., Cambridge
| | - G Frampton
- Clinical Genomics, Foundation Medicine, Inc., Cambridge
| | | | - P J Stephens
- Clinical Genomics, Foundation Medicine, Inc., Cambridge
| | - J A Elvin
- Department of Pathology, Foundation Medicine, Inc., Cambridge
| | - D W Bowles
- Division of Medical Oncology, University of Colorado School of Medicine, Aurora, USA. mailto:
| |
Collapse
|
14
|
Friedman P, Miller V, Fridman G, Fridman A. Various cold plasma devices for the treatment of actinic keratosis. J Eur Acad Dermatol Venereol 2018; 32:e445-e446. [DOI: 10.1111/jdv.14969] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
| | - V. Miller
- C&J Nyheim Plasma Institute; Drexel University; Camden NJ USA
| | - G. Fridman
- C&J Nyheim Plasma Institute; Drexel University; Camden NJ USA
| | - A. Fridman
- C&J Nyheim Plasma Institute; Drexel University; Camden NJ USA
| |
Collapse
|
15
|
Ikpeazu C, Elvin J, Vergilio J, Suh J, Ramkissoon S, Wang K, Bowles D, Somerset H, Russell J, Ali S, Schrock A, Fabrizio D, Frampton G, Miller V, Stephens P, Gay L, Ross J. Comprehensive Genomic Profiling and Precision Pathology for Clinically Advanced Salivary Gland Myoepithelial Carcinoma. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2017.12.186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
16
|
Suh J, Severson E, Hechtman J, Frampton G, Fabrizio D, Sun J, Ali S, Gu P, Klempner S, Miller V, Stephens P, Ross J. Hybrid-capture based comprehensive genomic profiling of hepatocellular carcinoma identifies patients who may benefit from targeted therapies and immune checkpoint blockade. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx660.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Ikeda S, Gay L, Pavlick D, Chung J, Ramkissoon S, Daniel S, Elvin J, Severson E, Bivona T, Reckamp K, Klempner S, Ou SH, Schrock A, Miller V, Stephens P, Ross J, Ganesan S, Lovly C, Mansfield A, Ali S. Comprehensive Genomic Profiling (CGP) of 114,200 advanced cancers identifies recurrent Kinase Domain Duplications (KDD) and novel oncogenic fusions in diverse tumor types. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx652] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Lin J, Zhu V, Yoda S, Yeap B, Jessop N, Schrock A, Dagogo-Jack I, Gowen K, Stephens P, Ross J, Ali S, Miller V, Gainor J, Hata A, Iafrate A, Ou S, Shaw A. MA 07.07 Clinical Outcomes and ALK Resistance Mutations in ALK+ Non-Small Cell Lung Cancer According to EML4-ALK Variant. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
19
|
Sun J, Li Y, Milbury C, Skoletsky J, Burns C, Yip W, Luo J, Dewal N, Johnson A, Gowen K, Tong J, He Y, He J, White J, Roels S, Tsuji A, Truesdell J, Peters E, Gilbert H, Wu C, Schleifman E, Barrett C, Thress K, Jenkins S, Elvin J, Otto G, Lipson D, Ross J, Miller V, Stephens P, Doherty M, Vietz C. P2.02-052 A Clinically-Validated Universal Companion Diagnostic Platform for Cancer Patient Care. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
20
|
Creeden J, Ross J, Vanden Borre P, Almog N, Schrock A, Chung J, Vergilio JA, Suh J, Ramkissoon S, Ali S, Miller V, Stephens P, Elvin J, Gay L. Comprehensive genomic profiling (CGP) of thymic gland carcinomas. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Skoulidis F, Albacker L, Hellmann M, Awad M, Gainor J, Goldberg M, Schrock A, Gay L, Elvin J, Ross J, Rizvi H, Carter B, Erasmus J, Halpenny D, Plodkowski A, Long N, Nishino-Habatu M, Denning W, Rodriguez-Canales J, Villalobos P, Cuentas EP, Sholl L, Sauter J, Elamin Y, Zhang J, Leonardi G, Wong K, Stephens P, Papadimitrakopoulou V, Wistuba I, Wolchok J, Shaw A, Jänne P, Rudin C, Miller V, Heymach J. MA 05.02 STK11/LKB1 Loss of Function Genomic Alterations Predict Primary Resistance to PD-1/PD-L1 Axis Blockade in KRAS-Mutant NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.479] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
22
|
Oztan A, Fischer S, Schrock AB, Erlich RL, Lovly CM, Stephens PJ, Ross JS, Miller V, Ali SM, Ou SHI, Raez LE. Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib. Lung Cancer 2017; 111:84-87. [PMID: 28838405 DOI: 10.1016/j.lungcan.2017.07.002] [Citation(s) in RCA: 62] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2017] [Revised: 07/03/2017] [Accepted: 07/05/2017] [Indexed: 11/26/2022]
Abstract
Mutations in the epidermal growth factor receptor (EGFR) are drivers for a subset of lung cancers. Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) recently approved for the treatment of T790M-positive non-small cell lung cancer (NSCLC); however, acquired resistance to osimertinib is evident and resistance mechanisms remain incompletely defined. The EGFR G724S mutation was detected using hybrid-capture based comprehensive genomic profiling (CGP) and a hybrid-capture based circulating tumor DNA (ctDNA) assays in two cases of EGFR-driven lung adenocarcinoma in patients who had progressed on osimertinib treatment. This study demonstrates the importance of both tissue and blood based hybrid-capture based genomic profiling at disease progression to identifying novel resistance mechanisms in the clinic.
Collapse
Affiliation(s)
- A Oztan
- Foundation Medicine, Inc., 150 Second Street, Cambridge, MA 02141, USA.
| | - S Fischer
- Providence Medical Institute, 2021 Santa Monica Blvd, Santa Monica, CA 90404, USA
| | - A B Schrock
- Foundation Medicine, Inc., 150 Second Street, Cambridge, MA 02141, USA
| | - R L Erlich
- Foundation Medicine, Inc., 150 Second Street, Cambridge, MA 02141, USA
| | - C M Lovly
- Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA
| | - P J Stephens
- Foundation Medicine, Inc., 150 Second Street, Cambridge, MA 02141, USA
| | - J S Ross
- Foundation Medicine, Inc., 150 Second Street, Cambridge, MA 02141, USA
| | - V Miller
- Foundation Medicine, Inc., 150 Second Street, Cambridge, MA 02141, USA
| | - S M Ali
- Foundation Medicine, Inc., 150 Second Street, Cambridge, MA 02141, USA
| | - S-H I Ou
- Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, CA 92868, USA
| | - L E Raez
- Memorial Cancer Institute/Memorial Healthcare System, 801 N. Flamingo Road, Pembroke Pines, FL 33028, USA
| |
Collapse
|
23
|
Xu L, Miller V, Fields N. BENEFITS AND BARRIERS FOR CHINESE IMMIGRANT FOSTER GRANDPARENTS: A MIXED METHODS STUDY. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- L. Xu
- The University of Texas at Arlington, Arlington, Texas
| | - V. Miller
- The University of Texas at Arlington, Arlington, Texas
| | - N. Fields
- The University of Texas at Arlington, Arlington, Texas
| |
Collapse
|
24
|
Daniel J, Ruzic A, Dalland J, Miller V, Hanna M. Management of mixed type congenital mesoblastic nephroma: Case series and review of the literature. J Neonatal Perinatal Med 2017; 10:113-118. [PMID: 28282819 DOI: 10.3233/npm-1617] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Congenital mesoblastic nephroma (CMN) is the most common renal tumor of infancy; however, it occurs infrequently with an incidence of 1 : 125,000. The cellular and classical variants are the most common subtypes of tumors, with a mixed variant occurring infrequently. We describe two cases of mixed variant CMN, which presented within days of each other differing in their clinical behavior. The first case followed a typical course, previously described in the literature, while the other deviated significantly. Traditionally, CMN presents as large abdominal mass in the neonatal period associated with a paraneoplastic syndrome, which can result in hypertension or hypercalcemia. Surgical resection is curative in most cases and long-term prognosis is excellent. Hypertension rarely persists after removal of the tumor, but remained in one of our two patients.
Collapse
Affiliation(s)
- J Daniel
- Department of Pediatrics, Division of Neonatology, College of Medicine, Univeristy of Kentucky, Lexington, KY, USA
| | - A Ruzic
- Department of Surgery, Division of Pediatric Surgery, College of Medicine, University of Kentucky, Lexington, KY, USA
| | - J Dalland
- Department of Pathology, College of Medicine, Univeristy of Kentucky, Lexington KY, USA
| | - V Miller
- Department of Pathology, College of Medicine, Univeristy of Kentucky, Lexington KY, USA
| | - M Hanna
- Department of Pediatrics, Division of Neonatology, College of Medicine, Univeristy of Kentucky, Lexington, KY, USA
| |
Collapse
|
25
|
Janku F, Vergilio J, Salhia B, Fanale M, Oki Y, Huang H, Westin J, He J, Nahas M, Mughal T, Miller V, Stephens P, Raina A, Garrido-Laguna I, Meric-Bernstam F, Ross J, Liang W. Comprehensive genomic profiling reveals recurrent XPO1 mutations and other alterations in archival samples of patients with Hodgkin lymphoma. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32705-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
26
|
Mehnert J, Ali S, Kulkarni A, Pavlick D, Goydos J, Chen S, Shrock A, Hirshfield K, Rodriguez L, Stein M, White E, Ross J, Miller V, Stephens P, Ganesan S. Landscape of RAF1 fusions in solid tumors and therapeutic utility of sorafenib. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)33022-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
27
|
Bobek H, Baldwin R, Miller V, Patel G, Shah S. P086 Silicone allergy and implantable cardioverter defibrillators: a patch test case study. Ann Allergy Asthma Immunol 2016. [DOI: 10.1016/j.anai.2016.09.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
28
|
Ali S, Kolla B, Bailey M, Schrock A, Klempner S, Frampton G, Fabrizio D, Ou SH, He J, Suh J, Ross J, Stephens P, Miller V, Patel M. Small cell lung carcinoma harbors targetable alterations including MYCL1 fusions responding to aurora kinase inhibitor. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw389.02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Gay L, Ross J, Wang K, Vergilio JA, Suh J, Ramkissoon S, Bowles D, Serracino H, Russell J, Ali S, Miller V, Stephens P, Elvin J. Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw376.04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Van Borre P, Schrock A, Anderson P, Heilmann A, Holmes O, Wang K, Khan S, Morris J, Ou SH, Waguespack S, Stephens P, Erlich R, Miller V, Ross J, Ali S. Pediatric, adolescent and young adult (PAYA) thyroid carcinoma harbors frequent and diverse targetable genomic alterations including kinase fusions. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw369.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Ali S, Fedorchak K, Schrock A, Johnson J, Gowen K, Elvin J, Vergilio JA, Klempner S, Mehra R, Ho A, Pavlick D, Suh J, Bordoni R, Jung D, Stephens P, Chung C, Ross J, Miller V. Advanced acinic cell carcinoma harbors kinase rearrangements including BRAF kinase domain duplications. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw376.32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Elvin J, Chalmers Z, Hou J, Del Priore G, Ali S, Vergilio J, Suh J, Chmielecki J, Frampton G, Lipson D, Stephens P, Miller V, Ross J, Wright J. Comprehensive genomic profiling of ovarian carcinomas identifies both ERBB2 amplifications and activating point mutations as biomarkers for anti-HER2 targeted therapy. Gynecol Oncol 2016. [DOI: 10.1016/j.ygyno.2016.04.457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
33
|
Miller V, Lin A, Kako F, Gabunia K, Kelemen S, Brettschneider J, Fridman G, Fridman A, Autieri M. Microsecond-pulsed dielectric barrier discharge plasma stimulation of tissue macrophages for treatment of peripheral vascular disease. Phys Plasmas 2015; 22:122005. [PMID: 26543345 PMCID: PMC4617731 DOI: 10.1063/1.4933403] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/13/2015] [Accepted: 06/17/2015] [Indexed: 05/19/2023]
Abstract
Angiogenesis is the formation of new blood vessels from pre-existing vessels and normally occurs during the process of inflammatory reactions, wound healing, tissue repair, and restoration of blood flow after injury or insult. Stimulation of angiogenesis is a promising and an important step in the treatment of peripheral artery disease. Reactive oxygen species have been shown to be involved in stimulation of this process. For this reason, we have developed and validated a non-equilibrium atmospheric temperature and pressure short-pulsed dielectric barrier discharge plasma system, which can non-destructively generate reactive oxygen species and other active species at the surface of the tissue being treated. We show that this plasma treatment stimulates the production of vascular endothelial growth factor, matrix metalloproteinase-9, and CXCL 1 that in turn induces angiogenesis in mouse aortic rings in vitro. This effect may be mediated by the direct effect of plasma generated reactive oxygen species on tissue.
Collapse
Affiliation(s)
- V Miller
- AJ Drexel Plasma Institute, Drexel University , Camden, New Jersey 08103, USA
| | - A Lin
- AJ Drexel Plasma Institute, Drexel University , Camden, New Jersey 08103, USA
| | - F Kako
- Department of Physiology, Independence Blue Cross Cardiovascular Research Center, Temple University School of Medicine , Philadelphia, Pennsylvania 19140, USA
| | - K Gabunia
- Department of Physiology, Independence Blue Cross Cardiovascular Research Center, Temple University School of Medicine , Philadelphia, Pennsylvania 19140, USA
| | - S Kelemen
- Department of Physiology, Independence Blue Cross Cardiovascular Research Center, Temple University School of Medicine , Philadelphia, Pennsylvania 19140, USA
| | - J Brettschneider
- AJ Drexel Plasma Institute, Drexel University , Camden, New Jersey 08103, USA
| | - G Fridman
- AJ Drexel Plasma Institute, Drexel University , Camden, New Jersey 08103, USA
| | - A Fridman
- AJ Drexel Plasma Institute, Drexel University , Camden, New Jersey 08103, USA
| | - M Autieri
- Department of Physiology, Independence Blue Cross Cardiovascular Research Center, Temple University School of Medicine , Philadelphia, Pennsylvania 19140, USA
| |
Collapse
|
34
|
Miller V, Ward K. Breast and Cervical Cancer Screening: Reaching Women with Disabilities in Alaska. Int J Epidemiol 2015. [DOI: 10.1093/ije/dyv096.557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Ali S, Choueiri T, Wang K, Khaira D, Johnson A, Squillace R, Elvin J, Chmielecki J, Yelensky R, Lipson D, Miller V, Ross J, Stein M, Pal S, Stephens P. 2651 Comprehensive genomic profiling (CGP) identifies unique and abundant clinically relevant genomic alterations in rare histologies of renal cell carcinoma. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31468-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
Ali S, Sanford E, Elvin J, Bailer M, He J, Wang K, Chmielecki J, Yelensky R, Morosini D, Lipson D, Frampton G, Chalmers Z, Stephens P, Ross J, Miller V, Pal S. 2641 Comprehensive genomic profiling of advanced penile carcinoma suggests a high rate of clinically relevant genomic alterations. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31458-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
37
|
Ali S, Wang K, Johnson A, Suh J, Heilmann A, Lipson D, Yelensky R, Chmielecki J, Elvin J, Konduri K, Subbiah V, Stephens P, Ross J, Miller V. 3007 Comprehensive genomic profiling characterizes the cpectrum of non-V600E activating BRAF alterations Including BRAF fusions in lung cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31652-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
38
|
Ross J, Chalmers Z, Wang K, Yelensky R, Lipson D, Elvin J, Vergilio J, Chmielecki J, Ali S, Miller V, Stephens P. 801 Therapeutically relevant extracellular domain mutations in ERBB2/HER2 are observed across multiple tumor types and are sssociated with major responses to anti-HER2 targeted therapies. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30391-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
39
|
Frampton G, Ali S, Rosenzweig M, Chmielecki J, Bauer T, Akimov M, Peters M, Bufill J, Lee C, Ou I, Salgia R, Yelensky R, Morosini D, Ross J, Philip S, Miller V. 464 Comprehensive genomic profiling of advanced cancers identifies MET exon 14 alterations that are sensitive to MET inhibitors. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30298-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
40
|
Miller V, Carruthers H, Morris J, Hasan SS, Archbold S, Whorwell PJ. Letter: efficacy of hypnotherapy in one thousand patients with irritable bowel syndrome--authors' reply. Aliment Pharmacol Ther 2015; 41:1223-4. [PMID: 25939472 DOI: 10.1111/apt.13205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/08/2022]
Affiliation(s)
- V Miller
- Neurogastroenterology Unit, Wythenshawe Hospital, Manchester, UK
| | | | | | | | | | | |
Collapse
|
41
|
Downe S, Finlayson K, Melvin C, Spiby H, Ali S, Diggle P, Gyte G, Hinder S, Miller V, Slade P, Trepel D, Weeks A, Whorwell P, Williamson M. Self-hypnosis for intrapartum pain management in pregnant nulliparous women: a randomised controlled trial of clinical effectiveness. BJOG 2015; 122:1226-34. [PMID: 25958769 PMCID: PMC4690197 DOI: 10.1111/1471-0528.13433] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/17/2015] [Indexed: 01/19/2023]
Abstract
Objective (Primary) To establish the effect of antenatal group self-hypnosis for nulliparous women on intra-partum epidural use. Design Multi-method randomised control trial (RCT). Setting Three NHS Trusts. Population Nulliparous women not planning elective caesarean, without medication for hypertension and without psychological illness. Methods Randomisation at 28–32 weeks’ gestation to usual care, or to usual care plus brief self-hypnosis training (two × 90-minute groups at around 32 and 35 weeks’ gestation; daily audio self-hypnosis CD). Follow up at 2 and 6 weeks postnatal. Main outcome measures Primary: epidural analgesia. Secondary: associated clinical and psychological outcomes; cost analysis. Results Six hundred and eighty women were randomised. There was no statistically significant difference in epidural use: 27.9% (intervention), 30.3% (control), odds ratio (OR) 0.89 [95% confidence interval (CI): 0.64–1.24], or in 27 of 29 pre-specified secondary clinical and psychological outcomes. Women in the intervention group had lower actual than anticipated levels of fear and anxiety between baseline and 2 weeks post natal (anxiety: mean difference −0.72, 95% CI −1.16 to −0.28, P = 0.001); fear (mean difference −0.62, 95% CI −1.08 to −0.16, P = 0.009) [Correction added on 7 July 2015, after first online publication: ‘Mean difference’ replaced ‘Odds ratio (OR)’ in the preceding sentence.]. Postnatal response rates were 67% overall at 2 weeks. The additional cost in the intervention arm per woman was £4.83 (CI −£257.93 to £267.59). Conclusions Allocation to two-third-trimester group self-hypnosis training sessions did not significantly reduce intra-partum epidural analgesia use or a range of other clinical and psychological variables. The impact of women's anxiety and fear about childbirth needs further investigation. Tweetable abstract Going to 2 prenatal self-hypnosis groups didn't reduce labour epidural use but did reduce birth fear & anxiety postnatally at < £5 per woman.
Collapse
Affiliation(s)
- S Downe
- Research in Childbirth and Health (ReaCH) group, University of Central Lancashire, Preston, UK
| | - K Finlayson
- Research in Childbirth and Health (ReaCH) group, University of Central Lancashire, Preston, UK
| | - C Melvin
- Women & Children's Health Research Team, East Lancashire Hospitals NHS Trust, Burnley General Hospital, Burnley, UK
| | - H Spiby
- Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham, UK
| | - S Ali
- Department of Health Sciences, University of York, York, UK
| | - P Diggle
- Lancaster Medical School, Lancaster University, Lancaster, UK
| | - G Gyte
- Cochrane Pregnancy and Childbirth Group, Department of Women and Childrens' Health, Liverpool Women's NHS Foundation Trust, University of Liverpool, Liverpool, UK
| | - S Hinder
- RaFT Research, Clitheroe, Lancashire, UK
| | - V Miller
- University Hospital of South Manchester NHS Foundation Trust, Manchester, UK
| | - P Slade
- Institute of Psychology Health and Society, University of Liverpool, Liverpool, UK
| | - D Trepel
- Department of Health Sciences, University of York, York, UK
| | - A Weeks
- Department of Women's and Children's Health, University of Liverpool, Liverpool, UK
| | - P Whorwell
- Centre for Gastrointestinal Sciences, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK
| | - M Williamson
- Women & Children's Health Research Team, East Lancashire Hospitals NHS Trust, Burnley General Hospital, Burnley, UK
| |
Collapse
|
42
|
Miller V, Carruthers HR, Morris J, Hasan SS, Archbold S, Whorwell PJ. Hypnotherapy for irritable bowel syndrome: an audit of one thousand adult patients. Aliment Pharmacol Ther 2015; 41:844-55. [PMID: 25736234 DOI: 10.1111/apt.13145] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2014] [Revised: 09/18/2014] [Accepted: 02/10/2015] [Indexed: 12/14/2022]
Abstract
BACKGROUND Gut-focused hypnotherapy improves the symptoms of irritable bowel syndrome (IBS) with benefits being sustained for many years. Despite this, the technique has not been widely adopted by healthcare systems, possibly due to relatively small numbers in published studies and uncertainty about how it should be provided. AIM To review the effect of hypnotherapy in a large cohort of refractory IBS patients. METHODS One thousand IBS patients fulfilling Rome II criteria, mean age 51.6 years (range 17-91 years), 80% female, receiving 12 sessions of hypnotherapy over 3 months, were studied. The primary outcome was a 50 point reduction in the IBS Symptom Severity Score. The fall in scores for Noncolonic Symptoms, Quality of Life and Anxiety or Depression, were secondary outcomes. The Federal Drug Administration's recommended outcome of a 30% or more reduction in abdominal pain was also recorded. RESULTS Overall, 76% met the primary outcome which was higher in females (females: 80%, males: 62%, P < 0.001) and those with anxiety (anxious: 79%, non-anxious: 71%, P = 0.010). The mean reduction in other scores was: IBS Symptom Severity Score, 129 points (P < 0.001), Noncolonic Symptom Score, 65 (P < 0.001) and Quality of Life Score, 66 (P < 0.001). Sixty-seven per cent reported a 30% or more reduction in abdominal pain scores. Pain days fell from 18 to 9 per month. Patients with anxiety and depression fell from 63% to 34% and 25% to 12% respectively (P < 0.001). Outcome was unaffected by bowel habit subtype. CONCLUSION These results provide further evidence that gut-focused hypnotherapy is an effective intervention for refractory IBS.
Collapse
Affiliation(s)
- V Miller
- Neurogastroenterology Unit, Wythenshawe Hospital, Manchester, UK
| | | | | | | | | | | |
Collapse
|
43
|
McClellan MB, Daniel GW, Dickson D, Perlmutter J, Berger DP, Miller V, Nussbaum S, Malin J, Romine MH, Schilsky RL. Improving evidence developed from population-level experience with targeted agents. Clin Pharmacol Ther 2015; 97:478-87. [PMID: 25676878 DOI: 10.1002/cpt.90] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2014] [Accepted: 02/05/2015] [Indexed: 12/14/2022]
Abstract
Off-label drug use is common in oncology, due in part to significant unmet medical need, the rarity of many cancers, and the difficulty of conducting randomized controlled trials (RCTs) to support labeling of every drug in every disease setting. As new drugs are developed for use in tumors defined by genomic aberrations, it may be scientifically reasonable to expect that a targeted anti-cancer agent with efficacy in a biomarker-defined population within one tumor type may also have activity in another tumor type expressing the same biomarker. Such expectations also fuel off-label prescribing. However, the current approach to prescribing targeted agents off-label does not capture patient outcomes, thus missing an opportunity to gather data that could validate this approach. We explore the potential for collecting such data, highlight two proposals for oncology-specific patient registries, and put forward considerations that should be addressed to move toward better evidence development around off-label use.
Collapse
|
44
|
Peethambaran B, Han J, Kermalli K, Jiaxing J, Fridman G, Balsamo R, Fridman AA, Miller V. Nonthermal Plasma Reduces Water Consumption While Accelerating Arabidopsis thaliana Growth and Fecundity. Plasma Med 2015. [DOI: 10.1615/plasmamed.2016015723] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
45
|
Chmielecki J, Frampton G, Morosini D, Ali S, Lipson D, Yelensky R, Ross J, Miller V, Stephens P. GE-07 * THE GENOMIC LANDSCAPE OF DIVERSE BRAIN TUMORS REVEALS KNOWN AND NOVEL ONCOGENIC ALTERATIONS FREQUENTLY ASSOCIATED WITH SENSITIVITY TO TARGETED INHIBITORS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou256.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
46
|
Abstract
AIM The aim of this grounded theory study was to explore mothers' perspectives of the processes of collaborative goal setting in multidisciplinary child development services involving follow-up home therapy. METHODS Semi-structured interviews were conducted in South East Queensland, Australia with 14 mothers of children aged 3-6 years who were accessing multidisciplinary child development services. Interviews were focussed around the process of goal setting. RESULTS A grounded theory of Maternal Roles in Goal Setting (The M-RIGS Model) was developed from analysis of data. Mothers assumed Dependent, Active Participator and Collaborator roles when engaging with the therapist in goal-setting processes. These roles were characterized by the mother's level of dependence on the therapist and insight into their child's needs and therapy processes. Goal Factors, Parent Factors and Therapist Factors influenced and added complexity to the goal-setting process. CONCLUSION The M-RIGS Model highlights that mothers take on a range of roles in the goal-setting process. Although family-centred practice encourages negotiation and collaborative goal setting, parents may not always be ready to take on highly collaborative roles. Better understanding of parent roles, goal-setting processes and influencing factors will inform better engagement with families accessing multidisciplinary child development services.
Collapse
Affiliation(s)
- S Forsingdal
- Child Development Service (Bayside) Child & Youth Community Health Service, Children's Health Queensland, Queensland Health, Brisbane, Queensland, Australia
| | | | | | | | | |
Collapse
|
47
|
Giltnane JM, Balko JM, Wang K, Kuba MG, Mehndi M, Stricker TP, Sanders ME, Yelensky R, Stephens PJ, Miller V, Arteaga CL. Abstract PD3-1: Serial next generation sequencing (NGS) of poor prognosis luminal tumors across treatment history reveals both de novo and acquired alterations potentially associated with endocrine resistance. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-pd3-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Cancer therapies exert selective pressure on genomically heterogeneous breast cancers and may select for alterations in genes associated with drug resistance or metastasis. We evaluated this hypothesis by comparing sequential primary, post-neoadjuvant chemotherapy, and recurrent metastatic tumor samples from 5 patients with aggressive hormone receptor positive (HR+) breast cancer.
Triplet samples (primary untreated, primary post-neoadjuvant chemotherapy, metastatic recurrence) were assessed in 5 patients with HR+ breast cancer. All patients were treated with cyclophosphamide and doxorubicin followed by paclitaxel or docetaxel, and adjuvant radiation and hormonal therapy. They all recurred during adjuvant antiestrogen treatment (12-43 months post-surgery). Metastatic sites included liver (2), ovary, brain, and pleural fluid. In these 5 tumor sets, we queried genomic alterations across 3,769 exons from 236 cancer genes using the FoundationOne™ NGS assay.
Gene amplifications were frequently discordant among the triplet biopsies; all patients showed copy number alterations and 3 of 5 patients had two or more additional gene amplifications confirmed only in the biopsy of the metastasis. ESR1 (ERa) mutations were identified in the metastatic lesions of 2/5 patients but not in the diagnostic biopsy or the post-neoadjuvant therapy mastectomy specimen; both also harbored de novo and concurrent GATA3 truncations. One of the ESR1 mutations, Y537S, is known to result in an estrogen-independent, transcriptionally active receptor. The same patient showed amplification of 11q13 genes CCND1, EMSY, and FGF19, an amplicon known to be associated with endocrine resistance. Concordant FGFR1 and ZNF703 amplifications, both at 8p12, were observed de novo in 2 other patients; these alterations have beenassociated with the luminal B subtype and resistance to antiestrogens. FGFR1/ZNF703 alterations were mutually exclusive with ESR1 mutations. The 5th tumor contained a PIK3CA ‘hot spot’ mutation in all 3 sequential biopsies. This tumor also exhibited IGF1R, IRS2, MYC and MCL1 gene amplification only in the metastasis. Overall, IGF1R amplifications were observed in 3/5 patients. In addition, amplification of ZNF217 at 20q13.2, an amplicon with known association with poor prognosis, was observed de novo in 2 patients that exhibited rapid recurrence on adjuvant therapy (12 and 17 months).
Acquired somatic alterations that deregulate ERα signaling may allow for escape from estrogen deprivation leading to treatment resistance. We speculate ESR1 mutations, rarely observed in primary breast tumors, are selected for during adjuvant hormonal treatment in aggressive HR+ breast cancer. Testing for de novo and acquired alterations throughout the clinical course of patients with ER+ cancers may identify targetable alterations, such as FGFR1 and IGF1R gene amplifications and others, against which targeted drugs are available. Studies are underway to validate these findings in additional patients with sequential samples and to investigate the function and therapeutic implications of ESR1 mutations.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr PD3-1.
Collapse
Affiliation(s)
- JM Giltnane
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Foundation Medicine, Cambridge, MA
| | - JM Balko
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Foundation Medicine, Cambridge, MA
| | - K Wang
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Foundation Medicine, Cambridge, MA
| | - MG Kuba
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Foundation Medicine, Cambridge, MA
| | - M Mehndi
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Foundation Medicine, Cambridge, MA
| | - TP Stricker
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Foundation Medicine, Cambridge, MA
| | - ME Sanders
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Foundation Medicine, Cambridge, MA
| | - R Yelensky
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Foundation Medicine, Cambridge, MA
| | - PJ Stephens
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Foundation Medicine, Cambridge, MA
| | - V Miller
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Foundation Medicine, Cambridge, MA
| | - CL Arteaga
- Vanderbilt-Ingram Cancer Center, Nashville, TN; Foundation Medicine, Cambridge, MA
| |
Collapse
|
48
|
Calton EK, Miller V, Soares MJ. Response to the letter of Kawada T on adiponectin and the metabolic syndrome. Eur J Clin Nutr 2013; 67:897. [DOI: 10.1038/ejcn.2013.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
49
|
Lipson D, He J, Yelensky R, Miller V, Sheehan C, Brennan K, Jarosz M, Stephens P, Cronin M, Ross J. Abstract PD02-07: Next-generation sequencing of FFPE breast cancers demonstrates high concordance with FISH in calling HER2 amplifications and commonly detects other clinically relevant genomic alterations. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-pd02-07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: As more therapies targeting genomic alterations become available, next-generation sequencing (NGS) is increasingly performed in tumor types where mutational status may drive treatment choice. In addition to its ability to identify base substitutions, insertions and deletions across entire exons, NGS can detect relevant copy number changes such as amplification of HER2 in breast tumors. However, for NGS to be clinically applicable, it must reliably analyze FFPE tumor samples and show concordance with the best current diagnostic methods.
Methods: To confirm a clinical role for NGS in detecting copy number alterations, we identified 35 FFPE invasive breast carcinomas previously tested for HER2 status by FISH, including 15 HER2 positives (≥7 copies) and 20 HER2 negatives (<4 copies) and sequenced 3,230 exons of 182 cancer genes including HER2, in a CLIA certified lab (Foundation Medicine). Average coverage depth of >900X uniquely-mapping reads was obtained. Sequence data were analyzed for HER2 copy number (blinded to FISH results) based on a statistical model using allele frequencies and coverage depth of HER2 exons versus a process-matched normal control, classifying cases as HER2 positive (≥6 average copies), HER2 negative (<4 copies), intermediate (4–5 copies) or unknown (<20% tumor purity). The data were also analyzed for additional clinically relevant genomic alterations.
Results: High concordance was noted between HER2 copy number status determined by FISH and NGS: 30 of the 35 samples were classified as positive or negative by NGS, 1 was classified as intermediate and 4 as unknown due to low purity. Using FISH as a gold standard, NGS HER2 calls demonstrated an accuracy of 97% (29/30, 95% CI 83–99%), 93% sensitivity (13/14, 95% CI 69–99%) and 100% specificity (16/16, 95% CI 81–100%). One discordant case was noted (FISH positive, NGS negative). Furthermore, NGS revealed 70 additional alterations (38 base substitutions, 10 insertions/deletions, 22 copy number alterations) in 23 cancer genes (an average of 2.0 alterations per sample). Genomic alterations that predict sensitivity or resistance to approved or experimental targeted therapies and thus plausibly guide treatment decisions were found in 69% of patients. These include PIK3CA (16 cases, PI3 kinase/mTOR inhibitors), PTEN (3 cases, PI3K/AKT/mTOR inhibitors), KRAS (1 case, resistance to cetuximab and panitumumab), and NF1 (1 case, mTOR/MAPK inhibitors) plus amplifications of CCND1 (4 cases, CDK4 inhibitors), FGFR1 (3 cases, FGF inhibitors) and MCL1 (3 cases, BCL-2 inhibitors, resistance to anti-tubulin therapies). Four cases included co-amplification of RARA with HER2.
Conclusions: We conclude that HER2 status can be reliably determined by NGS on FFPE breast cancers and that NGS uncovers additional actionable genomic alterations that could impact disease management in a high proportion of patients. Further evaluation of NGS as a guide to therapy in breast cancer is warranted.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr PD02-07.
Collapse
Affiliation(s)
- D Lipson
- Foundation Medicine, Inc, Cambridge, MA; Albany Medical College, Albany, NY
| | - J He
- Foundation Medicine, Inc, Cambridge, MA; Albany Medical College, Albany, NY
| | - R Yelensky
- Foundation Medicine, Inc, Cambridge, MA; Albany Medical College, Albany, NY
| | - V Miller
- Foundation Medicine, Inc, Cambridge, MA; Albany Medical College, Albany, NY
| | - C Sheehan
- Foundation Medicine, Inc, Cambridge, MA; Albany Medical College, Albany, NY
| | - K Brennan
- Foundation Medicine, Inc, Cambridge, MA; Albany Medical College, Albany, NY
| | - M Jarosz
- Foundation Medicine, Inc, Cambridge, MA; Albany Medical College, Albany, NY
| | - P Stephens
- Foundation Medicine, Inc, Cambridge, MA; Albany Medical College, Albany, NY
| | - M Cronin
- Foundation Medicine, Inc, Cambridge, MA; Albany Medical College, Albany, NY
| | - J Ross
- Foundation Medicine, Inc, Cambridge, MA; Albany Medical College, Albany, NY
| |
Collapse
|
50
|
Janjigian Y, Smit E, Horn L, Groen H, Camidge D, Gettinger S, Fu Y, Denis L, Miller V, Pao W. Activity of Afatinib/Cetuximab in Patients (PTS) with EGFR Mutant Non-Small Cell Lung Cancer (Nsclc) and Acquired Resistance (Ar) To EGFR Inhibitors. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33838-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|